<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cardiovascular effects of hypothyroidism</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cardiovascular effects of hypothyroidism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cardiovascular effects of hypothyroidism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Irwin Klein, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypothyroidism is characterized by a decrease in oxygen and substrate utilization by all the major organ systems of the body. As a result, the demands for cardiac output decrease; in addition, hypothyroidism directly alters cardiac function through changes in myocyte-specific gene expression [<a href="#rid1">1</a>]. This topic will review the cardiovascular manifestations of overt hypothyroidism. Other symptoms of hypothyroidism and cardiovascular manifestations of subclinical hypothyroidism are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The major cardiovascular changes that occur in hypothyroidism include a decrease in cardiac output and cardiac contractility, a reduction in heart rate, and an increase in peripheral vascular resistance (<a class="graphic graphic_figure graphicRef85918" href="/z/d/graphic/85918.html" rel="external">figure 1</a>) [<a href="#rid2">2,3</a>]. There are also significant changes in modifiable atherosclerotic risk factors, including hypercholesterolemia, diastolic hypertension, carotid intimal media thickness, and endothelial derived relaxation factor (nitric oxide), which accompany overt hypothyroidism [<a href="#rid1">1-5</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Cardiac contractility</span><span class="headingEndMark"> — </span>All measures of left ventricular performance are impaired in both short- and long-term hypothyroidism, leading to a reduction in cardiac output [<a href="#rid4">4,5</a>]. There is also a decrease in the rate of ventricular diastolic relaxation; as a result, compliance and diastolic filling are impaired [<a href="#rid6">6</a>].</p><p>The reduced ventricular performance is probably multifactorial. Possible mechanisms include increases in afterload and changes in expression of the genes for myocardial calcium regulatory proteins [<a href="#rid1">1,6</a>]. Several enzymes involved in regulating calcium fluxes in the heart are controlled by thyroid hormone, including the calcium-dependent adenosine triphosphatase and phospholamban [<a href="#rid3">3,7</a>]. Hypothyroidism-dependent decreases in the expression and activity of these enzymes could potentially impair systolic performance and diastolic relaxation [<a href="#rid6">6</a>]. Beta-adrenergic receptor expression is also decreased, resulting in a blunted response to catecholamine mediated increases in inotropy.</p><p class="headingAnchor" id="H4"><span class="h2">Vascular resistance</span><span class="headingEndMark"> — </span>Thyroid hormone relaxes vascular smooth muscle cells, thereby reducing peripheral vascular resistance [<a href="#rid3">3</a>]. Conversely, hypothyroidism causes a decrease in the release of endothelial-derived relaxing factor (EDRF), which in turn promotes contraction of these cells, thereby increasing peripheral vascular resistance [<a href="#rid2">2</a>]. This change results in reductions in cardiac output (in part because the heart cannot increase contractility to compensate) and tissue perfusion. Tissue oxygen utilization is also decreased; thus, arteriovenous (A-V) oxygen extraction is not different from that in normal subjects [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Symptoms and signs of cardiovascular dysfunction are not common or prominent in patients with hypothyroidism. Those that do occur include (<a class="graphic graphic_table graphicRef68946" href="/z/d/graphic/68946.html" rel="external">table 1</a>) [<a href="#rid1">1,3,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Exertional dyspnea and exercise intolerance, although these symptoms are probably due to skeletal muscle dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Bradycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension resulting from the increase in vascular resistance and the fall in endothelial-derived relaxing factor (EDRF) [<a href="#rid3">3</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac dysfunction with poor contractility, dilatation, or pericardial effusion</p><p class="bulletIndent1"><span class="glyph">●</span>Edema, often nonpitting</p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial effusions, which occur in approximately 25 percent of patients and may be quite large</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Rhythm disturbances</span><span class="headingEndMark"> — </span>In addition to a slow pulse rate, hypothyroid patients may have ventricular premature beats and rarely ventricular tachycardia with a long QT interval (torsade de pointes) [<a href="#rid8">8</a>] (see  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>). This can be especially problematic in patients with underlying ischemic heart disease or known ventricular arrhythmias. Treatment with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> can produce hypothyroidism and, in turn, further predispose the ischemic heart to ventricular arrhythmias. (See  <a class="medical medical_review" href="/z/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction", section on 'Hypothyroidism'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Blood pressure</span><span class="headingEndMark"> — </span>Thyroid hormone plays a role in blood pressure homeostasis. In patients who had undergone total thyroidectomy for thyroid cancer, withdrawal of thyroxine (T4) for six weeks results in an increase in serum norepinephrine and aldosterone concentrations and an increase in blood pressure with a greater rise in diastolic pressure (126/85 compared with 120/76 mmHg at baseline) [<a href="#rid9">9</a>]. Diastolic blood pressure may vary directly with serum thyroid-stimulating hormone (TSH) levels over the entire spectrum of thyroid disease [<a href="#rid1">1,9</a>].</p><p>Approximately 20 to 40 percent of hypothyroid patients have hypertension, even though cardiac output is reduced [<a href="#rid6">6,10</a>]. The hypertension is primarily diastolic, and the pulse pressure is diminished. In hypertensive hypothyroid patients, the serum levels of renin are low and there is an increased prevalence of salt sensitivity, confirming the importance of the increase in systemic vascular resistance [<a href="#rid1">1,8</a>]. Among large groups of patients with hypertension, however, hypothyroidism is a contributory factor in only a small percentage [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Cardiac dysfunction</span><span class="headingEndMark"> — </span>The upstroke of the pulse may be slow and the left ventricular apical impulse weak [<a href="#rid5">5</a>]. The heart may be enlarged and the heart sounds distant. These findings, plus dyspnea, exercise intolerance, and edema, may make it seem as if the patient has heart failure. While heart failure due solely to hypothyroidism is rare [<a href="#rid3">3</a>], in patients with underlying or preexistent cardiac disease, the presence or development of hypothyroidism leads to more severe heart failure, higher levels of brain natriuretic peptide (BNP) [<a href="#rid7">7</a>], and worse short-term hospital outcomes [<a href="#rid11">11</a>].</p><p>Electrocardiograms may show low voltage and nonspecific ST segment and Q wave changes. Occasionally, large pericardial effusion can occur, characterized by a high protein and cholesterol content (<a class="graphic graphic_diagnosticimage graphicRef65059" href="/z/d/graphic/65059.html" rel="external">image 1</a>). These are rarely hemodynamically important and should be managed with thyroid hormone replacement, not by needle or surgical drainage. The latter can lead to hemodynamic worsening [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Coronary artery disease</span><span class="headingEndMark"> — </span>Patients with angina pectoris probably have symptoms less often if they become hypothyroid because they are less active and peripheral oxygen demands decrease. The occurrence of anginal-like pain in some hypothyroid patients and the frequent occurrence of hypercholesterolemia diastolic hypertension, and elevated homocysteine levels have led to suggestions that hypothyroidism is associated with accelerated coronary artery disease [<a href="#rid1">1,5</a>].</p><p>Potential mechanisms in addition to lipid abnormalities and diastolic hypertension include elevated concentrations of C-reactive protein and endothelial dysfunction [<a href="#rid2">2,13,14</a>].</p><p>The potential risk of coronary artery disease in subclinical hypothyroidism is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Edema</span><span class="headingEndMark"> — </span>Periorbital edema and nonpitting edema of the hands and feet are characteristic features of hypothyroidism, albeit rare today. Nonpitting edema is due to interstitial accumulation of glycosaminoglycans (hyaluronic acid and chondroitin sulfate), with associated extravascular water retention at the same time that plasma volume is decreased [<a href="#rid3">3,4,15</a>]. Some patients have pitting edema of the feet and legs, probably secondary to an increase in albumin content of the interstitial fluid [<a href="#rid16">16</a>]. Ascites, pleural, and scrotal effusions may also be present.</p><p class="headingAnchor" id="H11"><span class="h2">Laboratory tests</span></p><p class="headingAnchor" id="H12"><span class="h3">Lipids</span><span class="headingEndMark"> — </span>Dyslipidemia is common in hypothyroidism. The usual findings are high serum total and low-density lipoprotein (LDL) cholesterol concentrations. Some patients have high serum very low-density lipoprotein (VLDL) cholesterol concentrations, and a few have hypertriglyceridemia. Lipid abnormalities in hypothyroidism are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7857.html" rel="external">"Lipid abnormalities in thyroid disease"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Homocysteine</span><span class="headingEndMark"> — </span>Some patients with hypothyroidism have high serum homocysteine concentrations, which fall toward, if not to, normal with T4 therapy [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Creatine kinase</span><span class="headingEndMark"> — </span>Many hypothyroid patients have high serum creatine kinase (CK) concentrations. The isoenzyme distribution is almost completely MM, with less than 4 percent constituting MB, indicating skeletal muscle, not myocardial, origin [<a href="#rid18">18</a>]. However, as many as 14 percent of patients with hypothyroidism have a raised serum concentration of CK-MB, which can be confusing in the evaluation of chest pain. This problem is obviated by measurement of serum troponin I, which is normal in hypothyroidism [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">EFFECT OF TREATMENT</span><span class="headingEndMark"> — </span>The changes in cardiovascular function in hypothyroidism respond to replacement therapy with T4 (<a class="graphic graphic_figure graphicRef63451" href="/z/d/graphic/63451.html" rel="external">figure 2</a>) [<a href="#rid5">5</a>]. In older patients or those with a history of angina, it is wise to begin therapy with a low dose of T4 because of the possibility of inducing an arrhythmia or an exacerbation of angina. Patients with coronary artery disease without other cardiopulmonary problems who have had recent successful interventions to treat ischemia (eg, coronary artery bypass grafting [CABG] or coronary artery stenting) are candidates for more conventional initial dosing. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Older patients or those with coronary heart disease'</a>.)</p><p>A 1961 report remains the largest and best study of the effects of beginning thyroid hormone on chest pain in patients with hypothyroidism [<a href="#rid19">19</a>]. Among 1503 hypothyroid patients, the following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Fifty-five patients had angina before thyroid hormone replacement therapy. During therapy, 21 improved, 25 had no change, and 9 had more angina.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thirty-five patients developed new angina during therapy, 6 during the first month, 6 during the first year, and 23 after 1 year.</p><p></p><p>Thus, angina may improve, and it does not often appear during T4 replacement therapy.</p><p>In patients with overt hypothyroidism, T4 therapy for several months raises the 24-hour heart rate by approximately 10 percent. It usually does not increase the frequency of premature atrial complex (PAC; also referred to as a premature atrial beat, premature supraventricular complex, or premature supraventricular beat; 22 of 25 patients had no increase in one study [<a href="#rid20">20</a>]) or of premature ventricular beats. TSH measurements should guide treatment to assure precise replacement into the optimal euthyroid range.</p><p>The clearance of coagulation factors is decreased in hypothyroidism [<a href="#rid21">21</a>]. In patients being treated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation, the dose required to maintain a therapeutic prothrombin time increases during hypothyroidism, and this increase is reversed with restoration of a normal TSH [<a href="#rid1">1</a>].</p><p>The long-term cardiovascular outcomes of patients treated for overt hypothyroidism are unclear. A population-based study assessed mortality and vascular outcomes among 15,889 treated individuals and 524,152 subjects in the general population [<a href="#rid22">22</a>]. Excess cardiovascular morbidity from arrhythmias and nonfatal ischemic heart and cerebrovascular disease was observed among those treated for hypothyroidism [<a href="#rid22">22</a>]. However, there was no increase in all-cause mortality. The long-term cardiovascular effects of treatment of patients with subclinical hypothyroidism are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults", section on 'Cardiovascular disease'</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular changes</strong> – The major cardiovascular changes that occur in hypothyroidism include a decrease in cardiac output and cardiac contractility, a reduction in heart rate, and an increase in peripheral vascular resistance. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac clinical manifestations</strong> – Symptoms of cardiovascular dysfunction are not common or prominent in patients with hypothyroidism. They may include exertional dyspnea, exercise intolerance, and edema. Findings on physical examination may include bradycardia, hypertension, nonpitting edema, and pleural or pericardial effusion (<a class="graphic graphic_table graphicRef68946" href="/z/d/graphic/68946.html" rel="external">table 1</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">Dyslipidemia is common in hypothyroidism. The usual findings are high serum total and low-density lipoprotein (LDL) cholesterol concentrations. (See <a class="local">'Lipids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of treatment</strong> – The changes in cardiovascular function in hypothyroidism respond to replacement therapy with thyroxine (T4) (<a class="graphic graphic_figure graphicRef63451" href="/z/d/graphic/63451.html" rel="external">figure 2</a>). (See <a class="local">'Effect of treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116:1725.</a></li><li><a class="nounderline abstract_t">Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003; 88:3731.</a></li><li><a class="nounderline abstract_t">Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344:501.</a></li><li><a class="nounderline abstract_t">GRAETTINGER JS, MUENSTER JJ, CHECCHIA CS, et al. A correlation of clinical and hemodynamic studies in patients with hypothyroidism. J Clin Invest 1958; 37:502.</a></li><li><a class="nounderline abstract_t">Crowley WF Jr, Ridgway EC, Bough EW, et al. Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med 1977; 296:1.</a></li><li class="breakAll">Klein I, Biondi B. Endocrine disorders and cardiovascular disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Bonow RO, Mann DL, Tomaselli GF, Bhatt D (Eds), Saunders Elsevier, Philadelphia 2019. p.1807.</li><li><a class="nounderline abstract_t">Selvaraj S, Klein I, Danzi S, et al. Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol 2012; 110:234.</a></li><li><a class="nounderline abstract_t">Fredlund BO, Olsson SB. Long QT interval and ventricular tachycardia of "torsade de pointe" type in hypothyroidism. Acta Med Scand 1983; 213:231.</a></li><li><a class="nounderline abstract_t">Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002; 87:1996.</a></li><li><a class="nounderline abstract_t">Gumieniak O, Perlstein TS, Hopkins PN, et al. Thyroid function and blood pressure homeostasis in euthyroid subjects. J Clin Endocrinol Metab 2004; 89:3455.</a></li><li><a class="nounderline abstract_t">Rothberger GD, Gadhvi S, Michelakis N, et al. Usefulness of Serum Triiodothyronine (T3) to Predict Outcomes in Patients Hospitalized With Acute Heart Failure. Am J Cardiol 2017; 119:599.</a></li><li><a class="nounderline abstract_t">Kabadi UM, Kumar SP. Pericardial effusion in primary hypothyroidism. Am Heart J 1990; 120:1393.</a></li><li><a class="nounderline abstract_t">Lekakis J, Papamichael C, Alevizaki M, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997; 7:411.</a></li><li><a class="nounderline abstract_t">Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 2004; 24:1.</a></li><li><a class="nounderline abstract_t">Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 1989; 10:366.</a></li><li><a class="nounderline abstract_t">Parving HH, Hansen JM, Nielsen SL, et al. Mechanisms of edema formation in myxedema--increased protein extravasation and relatively slow lymphatic drainage. N Engl J Med 1979; 301:460.</a></li><li><a class="nounderline abstract_t">Catargi B, Parrot-Roulaud F, Cochet C, et al. Homocysteine, hypothyroidism, and effect of thyroid hormone replacement. Thyroid 1999; 9:1163.</a></li><li><a class="nounderline abstract_t">Klein I, Mantell P, Parker M, Levey GS. Resolution of abnormal muscle enzyme studies in hypothyroidism. Am J Med Sci 1980; 279:159.</a></li><li><a class="nounderline abstract_t">KEATING FR Jr, PARKIN TW, SELBY JB, DICKINSON LS. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 1961; 3:364.</a></li><li><a class="nounderline abstract_t">Polikar R, Feld GK, Dittrich HC, et al. Effect of thyroid replacement therapy on the frequency of benign atrial and ventricular arrhythmias. J Am Coll Cardiol 1989; 14:999.</a></li><li><a class="nounderline abstract_t">Kurnik D, Loebstein R, Farfel Z, et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83:107.</a></li><li><a class="nounderline abstract_t">Flynn RW, Macdonald TM, Jung RT, et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006; 91:2159.</a></li></ol></div><div id="topicVersionRevision">Topic 7852 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17923583" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Thyroid disease and the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915662" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172193" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thyroid hormone and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13539188" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A correlation of clinical and hemodynamic studies in patients with hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/830262" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/830262" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22502900" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6133415" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long QT interval and ventricular tachycardia of "torsade de pointe" type in hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994331" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15240631" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Thyroid function and blood pressure homeostasis in euthyroid subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28017303" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Usefulness of Serum Triiodothyronine (T3) to Predict Outcomes in Patients Hospitalized With Acute Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2248183" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pericardial effusion in primary hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9226212" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249698" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hypothyroidism as a risk factor for cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2673756" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Connective tissue, glycosaminoglycans, and diseases of the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/460364" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mechanisms of edema formation in myxedema--increased protein extravasation and relatively slow lymphatic drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10646653" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Homocysteine, hypothyroidism, and effect of thyroid hormone replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7424961" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Resolution of abnormal muscle enzyme studies in hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13752096" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of heart disease associated with myxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2477427" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of thyroid replacement therapy on the frequency of benign atrial and ventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028964" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537678" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mortality and vascular outcomes in patients treated for thyroid dysfunction.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
